MedPath

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Not Applicable
Completed
Conditions
Hypertriglyceridemia
Interventions
Drug: 4/day of 4g P-OM3 capsules
Drug: 4/day of 1g P-OM3 capsules
Registration Number
NCT00504309
Lead Sponsor
Penn State University
Brief Summary

The purpose of this study is to evaluate the cardiovascular and lipid effects of two doses of an omega-3 fatty acid concentrate in a group of people who normally are not treated for high lipids.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • triglycerides 150-500 mg/dL
  • age 21-65 years
  • generally healthy
  • body mass index (BMI) 20-39 kg/m2
Exclusion Criteria
  • smoking
  • premenopausal (if female)
  • use of hormone replacement or oral contraceptives
  • use of lipid lowering or blood pressure medication
  • hypertension (blood pressure > 150/95 mm Hg)
  • peripheral vascular disease
  • heart disease, diabetes, or stroke
  • inflammatory disease (e.g. rheumatoid arthritis or Crohn's)
  • elevated liver enzymes
  • high intake of omega-3 containing foods
  • allergy to adhesive or latex
  • use of aspirin, anticoagulants, or SSRI

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Placebo, then 1g P-OM3, then 4g P-OM3Corn Oil Placebo, 4 capsules/day for 8 weeksCorn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
1g P-OM3, then 4g P-OM3, then PlaceboCorn Oil Placebo, 4 capsules/day for 8 weeks1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
Placebo, then 4g P-OM3, then 1g P-OM3Corn Oil Placebo, 4 capsules/day for 8 weeksCorn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
1g P-OM3, then Placebo, then 4g P-OM3Corn Oil Placebo, 4 capsules/day for 8 weeks1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
1g P-OM3, then 4g P-OM3, then Placebo4/day of 1g P-OM3 capsules1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
Placebo, then 4g P-OM3, then 1g P-OM34/day of 1g P-OM3 capsulesCorn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
1g P-OM3, then Placebo, then 4g P-OM34/day of 4g P-OM3 capsules1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
4g P-OM3, then 1g P-OM3, then PlaceboCorn Oil Placebo, 4 capsules/day for 8 weeks4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
1g P-OM3, then Placebo, then 4g P-OM34/day of 1g P-OM3 capsules1g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
Placebo, then 1g P-OM3, then 4g P-OM34/day of 1g P-OM3 capsulesCorn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
4g P-OM3, then 1g P-OM3, then Placebo4/day of 4g P-OM3 capsules4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
1g P-OM3, then 4g P-OM3, then Placebo4/day of 4g P-OM3 capsules1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks,followed by 6-wk washout. Placebo capsules for 8-wks.
4g P-OM3, then Placebo, then 1g P-OM34/day of 4g P-OM3 capsules4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
4g P-OM3, then 1g P-OM3, then Placebo4/day of 1g P-OM3 capsules4 g/day Dose Prescription Omega-3 acid ethyl esters (P-OM3)capsules(4) for first intervention (8 weeks), followed by 1g/day P-OM3 capsules(4) for 2nd intervention (8 weeks), followed by Placebo corn oil capsules, 4/day, for the 3rd intervention (8 weeks).
Placebo, then 4g P-OM3, then 1g P-OM34/day of 4g P-OM3 capsulesCorn Oil placebo capsules for 8-wks, followed by 6-wk washout. 4g P-OM3 capsules for 8-wks, followed by 6-wk washout. 1g P-OM3 for 8-wks.
4g P-OM3, then Placebo, then 1g P-OM3Corn Oil Placebo, 4 capsules/day for 8 weeks4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
4g P-OM3, then Placebo, then 1g P-OM34/day of 1g P-OM3 capsules4g capsules for 8-wks, followed by 6-wk washout. Placebo capsules for 8-wks, followed by 6-wk washout. 1g capsules for 8 wks.
Placebo, then 1g P-OM3, then 4g P-OM34/day of 4g P-OM3 capsulesCorn oil placebo capsules for 8-wks, followed by 6-wk washout.1g capsules for 8-wks, followed by 6-wk washout. 4g capsules for 8 wks.
Primary Outcome Measures
NameTimeMethod
Blood Pressure8 weeks

Effect of P-OM3 dose on blood pressure

Flow-mediated Dilation (FMD)8 weeks

Effect of P-OM3 dose on FMD, which is measured as percent change in brachial artery diameter at peak dilation vs. baseline following a 5-minute occlusion period.

Heart Rate8 weeks

Effect of P-OM3 dose on heart rate

Lipid Profile8 weeks

Plasma/serum samples were analyzed at baseline and at the end of each 8-week treatment period to evaluate the effect of P-OM3 dose on triglycerides, HDL-C, LDL-C, and total cholesterol.

Secondary Outcome Measures
NameTimeMethod
Cytokine Inflammatory Markers8 weeks

Effect of P-OM3 dose on concentrations of circulating inflammatory markers in plasma

Fasting Glucose8 weeks

Effect of P-OM3 dose on fasting glucose

Erythrocyte Fatty Acids8 weeks

Effect of P-OM3 dose on the percent concentration of select omega-3 fatty acids in red blood cells

Fasting Insulin8 weeks

Effect of P-OM3 dose on fasting insulin

Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) and Quantitative Insulin Sensitivity Check Index (QUICKI)8 weeks

Effect of P-OM3 dose on the homeostatic model assessment of insulin resistance (HOMA-IR) and the quantitative insulin sensitivity check index (QUICKI).

HOMA-IR calculates an index of insulin resistance and is calculated as follows: HOMA-IR = (glucose mg/dL \* insulin mU/L) / 405.

QUICKI is calculated as follows: QUICKI = 1 / (log(fasting insulin µU/mL) + log(fasting glucose mg/dL)).

Psychosocial Profile Questionnaires8 weeks

Effect of P-OM3 dose on psychosocial questionnaires:

Perceived Stress Scale (PSS)

* 14 questions, scored 0-4 based on how often the subject felt certain emotions

* Scores: 0 to 40; higher scores indicate higher perceived stress

Spielberger State Anxiety Inventory

* Levels of state anxiety (situational) and trait anxiety; 40 items scored by a Likert scale

* Scores: 20 to 80; higher scores indicate higher levels of anxiety

Positive and Negative Affect Scales (PANAS)

* Two 10-item scales; each item is rated on a Likert scale of 1 (not at all) to 5 (very much).

* Scores: 10 to 50, with higher scores representing higher levels of positive or negative affect

Center for Epidemiologic Studies Depression (CES-D) Scale

* 20 questions about symptoms of depression in the past week

* Scores: 0 to 60; higher scores indicate more symptomology. Score of 16 or higher indicates a risk for depression and should be followed by further evaluation by a qualified health professional

C-reactive Protein (CRP)8 weeks

Effect of P-OM3 dose on the plasma concentration of the inflammatory marker CRP

Trial Locations

Locations (1)

Penn State University General Clinical Research Center

🇺🇸

University Park, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath